Public, NASDAQ:XOMA
NASDAQ Global Market
Xoma Ltd (XOM.BE) holdings reduced by Lotsoff Capital Management
Date: Sat, 19 Jul 2008 12:10:59 GMT
Tags:
Xoma Ltd (XOM.BE) holdings reduced by Lotsoff Capital Management
Mffais.com - 13 hours ago
Mffais.com - 13 hours ago
LONG BEACH ( Mffais . com ) - Lotsoff Capital Management sold - 22,600 ( - 29.81 % ) of their shares in Xoma Ltd ( XOM.BE ) , bringing their current holdings to 53,200 shares as shown by filings ...
XOMA to Present Data Of Phase 1 Type 2 Diabetes Study
Date: Tue, 15 Jul 2008 19:24:14 GMT
Tags:
XOMA to Present Data Of Phase 1 Type 2 Diabetes Study
RTT News - Jul 15, 2008
RTT News - Jul 15, 2008
( RTTNews ) - Tuesday , biopharmaceutical company XOMA Ltd . ( XOMA : News , Chart , Quote ) said it would present results from two ongoing Phase 1 studies of XOMA 052 in Type 2 diabetes examining ...
Xoma to present data from Phase I study of XOMA 052 in Type 2 diabetes - Quick facts - RTT NewsXOMA reports XOMA 052 is well-tolerated in two Phase I studies
Date: Tue, 15 Jul 2008 13:16:22 GMT
Tags:
XOMA reports XOMA 052 is well-tolerated in two Phase I studies
Forbes - Jul 15, 2008
Forbes - Jul 15, 2008
BOSTON ( Thomson Financial ) - XOMA Ltd.Tuesday said results from two ongoing Phase I studies of XOMA 052 in Type 2 diabetes showed that the drug was well tolerated without any evidence of serious ...
XOMA 052 Phase 1 Data to be Presented At European Association for the Study of Diabetes Annual Meeting
Date: Tue, 15 Jul 2008 11:39:11 GMT
Tags:
XOMA 052 Phase 1 Data to be Presented At European Association for the Study of Diabetes Annual Meeting
MarketWatch - Jul 15, 2008
MarketWatch - Jul 15, 2008
, , ) , a leader in the discovery and development of antibody therapeutics , today announced that results from two ongoing Phase 1 studies of XOMA 052 in Type 2 diabetes will be presented at ...
2008-07-02 16:37:16 - www.companiesandmarkets.com adds new report - XOMA Limited - Premium Company Profile
Date: Wed, 02 Jul 2008 14:42:28 GMT
Tags:
2008-07-02 16:37:16 - www.companiesandmarkets.com adds new report - XOMA Limited - Premium Company Profile
PR-Inside.com (Pressemitteilung) - Jul 2, 2008
PR-Inside.com (Pressemitteilung) - Jul 2, 2008
XOMA is a biopharmaceutical company focusing on the discovery and development of therapeutic antibodies for the treatment of cancer and immune diseases.The company has a broad technology platform ...
XOMA 052 Phase 1 Data to be Presented At European Association for the Study of Diabetes Annual Meeting (PrimeNewswire)
Date: Tue, 15 Jul 2008 11:30:00 Etc/GMT
Tags:
BERKELEY, Calif., July 15, 2008 -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, today announced that results from two ongoing Phase 1 studies of XOMA 052 in Type 2 diabetes will be presented at the 44th European Association for the Study of Diabetes Annual Meeting that will be held in Rome, Italy on September 7-11, 2008.
XOMA to Present At the Jefferies Healthcare Conference On June 26 (PrimeNewswire)
Date: Thu, 19 Jun 2008 20:35:00 Etc/GMT
Tags:
XOMA 052 Demonstrates Anti-Inflammatory Effect in Arthritis Animal Studies; Data Presented At FOCIS (PrimeNewswire)
Date: Sat, 7 Jun 2008 18:00:00 Etc/GMT
Tags:
SAN FRANCISCO, June 7, 2008 -- XOMA Ltd. announced today at the Federation of Clinical Immunology Societies 2008 FOCIS Annual Meeting that a study of XOMA 052 in a mouse model of rheumatoid arthritis demonstrated that XOMA 052 significantly reduced the bone and cartilage destruction caused by collagen-induced arthritis and effectively prevented and treated disease as assessed by a standard measure of inflammation and swelling.
XOMA 052 Demonstrates Anti-Inflammatory Effects in Diabetes Animal Studies; Data Presented At ADA (PrimeNewswire)
Date: Sat, 7 Jun 2008 17:00:00 Etc/GMT
Tags:
SAN FRANCISCO, June 7, 2008 -- XOMA Ltd. announced today at the American Diabetes Association's 68th Scientific Sessions that a study of XOMA 052, a potent anti-inflammatory drug candidate, preserved insulin production, reduced fasting glucose and cholesterol levels and preserved beta-cell function in mice with a diet-induced obesity model of Type 2 diabetes.
XOMA to Present At the Needham Biotechnology and Medical Technology Conference On June 11 (PrimeNewswire)
Date: Thu, 5 Jun 2008 20:35:00 Etc/GMT
Tags: